miRNAs and neural stem cells: A team to treat Parkinson's disease?
miRNAs and neural stem cells: A team to treat Parkinson's disease?
复制标题
DOI：
10.4161/rna.19984
复制
发表时间：
2012-06
期刊：
影响因子：
4.1
通讯作者：
T. Palm;L. Bahnassawy;J. Schwamborn
中科院分区：
文献类型：
--
作者：
T. Palm;L. Bahnassawy;J. Schwamborn
帕金森病（PD）是一种常见的神经退行性疾病，目前尚无有效的神经保护或神经恢复疗法。在疾病进展期间，发生中枢神经系统的多巴胺能神经元的变性。因此，需要旨在抑制这种变性或替代变性神经元的疗法。一方面，可以通过特异性抑制疾病相关基因如α-突触核蛋白或富含亮氨酸重复序列激酶2（LRRK 2）来实现变性的阻止。另一方面，基于具有产生新的多巴胺能神经元的能力的神经干细胞，可以完成变性细胞的替代。由于这两种方法都可以通过micro-RNA进行调节，因此这些分子具有巨大的治疗潜力。在这篇综述中，我们将重点关注miRNAs的神经生物学和神经退行性影响，并强调它们在干细胞命运决定中的作用。最后，我们将讨论它们作为帕金森病治疗药物和靶点的潜力。
Parkinson's disease (PD) is a common neurodegenerative disorder with no proven neuroprotective or neurorestorative therapies. During disease progression, degeneration of dopaminergic neurons of the central nervous system occurs. Therefore, therapies that either aim on the inhibition of this degeneration or on the replacement of the degenerated neurons are needed. On the one hand, arrest of degeneration might be achievable through specific inhibition of disease associated genes like α-Synuclein or Leucine rich repeat kinase 2 (LRRK2). On the other hand, based on neural stem cells that bear the ability to generate new dopaminergic neurons, replacement of degenerated cells could be accomplished. Since both approaches can be regulated by micro-RNAs, these molecules have an enormous therapeutic potential. In this review, we will focus on the neurobiological and neurodegenerative implications of miRNAs and highlight their role in stem cell fate decisions. Finally, we will discuss their potential as therapeutic agents and targets for Parkinson's disease.